HI
HUNTINGTON INGALLS INDUSTRIES, INC. (HII)·Q1 2025 Earnings Summary
Executive Summary
- Q1 2025 revenue was $2.734B (-2.5% YoY; -9.0% QoQ), while diluted EPS was $3.79 (+20% QoQ; -2% YoY). Backlog ended at $48.0B with $2.1B in new awards . EPS beat Street, revenue was slightly below [Q1 2025 consensus EPS $2.88*, revenue $2.786B* vs actual $3.79 and $2.734B].
- Segment performance mixed: Newport News Shipbuilding (NNS) margin improved on contract incentives; Mission Technologies expanded margin; Ingalls margin stepped down on amphib program performance .
- Free cash flow was -$462M on timing of incentives and working capital (in line with quarterly guide), dividend paid was $1.35/share; cash balance $167M; liquidity ~$1.5B; a $500M note was repaid post-quarter .
- Guidance reaffirmed: FY25 shipbuilding revenue $8.9–$9.1B; shipbuilding operating margin 5.5–6.5%; Mission Technologies revenue $2.9–$3.1B, margin 4.0–4.5%; FY25 FCF $300–$500M. Q2 FCF $200–$300M; shipbuilding margins guided near low end .
- Catalysts: cost-type 2-boat Block V award (supports workforce and parts availability), outsourcing ramp, HD Hyundai MOU, and uncrewed/laser wins in Mission Technologies .
What Went Well and What Went Wrong
-
What Went Well
- NNS margin improved to 6.1% on Virginia-class incentives and Columbia volume; consolidated operating margin rose to 5.9% (+40 bps YoY) .
- Mission Technologies margin expanded to 5.4% (from 3.7% YoY) with strong performance in cyber, EW & space and uncrewed systems .
- Strategic momentum: signed MOU with HD Hyundai to accelerate ship production; delivered first Lionfish UUVs; selected to develop high-energy laser counter-UAS prototype .
- Management quote: “We intend to reach our goal of $250 million in annualized cost reduction by year's end” .
-
What Went Wrong
- Revenue declined across all segments (NNS, Ingalls, Mission Tech) on lower volumes, and consolidated revenue fell 2.5% YoY .
- Free cash flow was -$462M (low end of planned range) due to timing of incentives and program receipts/disbursements; cash from operations was -$395M .
- CVN 80 progress impacted by late major equipment deliveries; Ingalls amphib programs pressured margins; Q2 shipbuilding margins guided near low end (conservatism) .
- Analyst concerns about Ingalls margin trajectory and positive EACs; management acknowledged neutral EACs (80 up/80 down net zero) and experience/parts drag post-COVID .
Financial Results
Segment Breakdown – Ingalls Shipbuilding
Segment Breakdown – Newport News Shipbuilding
Segment Breakdown – Mission Technologies
KPIs
Guidance Changes
Earnings Call Themes & Trends
Management Commentary
- “First quarter revenue was $2.7 billion and earnings per share was $3.79. We ended the first quarter with backlog of $48 billion, of which approximately $28 billion is currently funded.”
- “Plans are in place, and we intend to reach our goal of $250 million in annualized cost reduction by year's end.”
- “Newport News is modestly behind plan… CVN 80… late major equipment… Once this equipment is received… we anticipate an acceleration of progress.”
- “We guided 5.5% for the quarter… landed about 90 bps above… EAC adjustments: 80 up and 80 down for a net of 0.”
- “We expect second quarter free cash flow to be between $200 million and $300 million.”
Q&A Highlights
- Contract type shift: FY’24 2-boat Block V is cost-type (CPIF) designed for affordability/profitability and workforce/equipment/facility investments; forms basis for Block VI & Columbia Build II, but future contract types will be situation-specific .
- Margins outlook: Q1 shipbuilding margin exceeded guide; Q2 guided conservatively given incentive timing and risk burn-down; MT Q1 performance strong (CEW & uncrewed) .
- Workforce/attrition: ~1,000 experienced craft hires; attrition improving though not back to pre-COVID; wage support implementation pending labor discussions .
- Outsourcing quality and schedule: On track at both yards with pilot-first approach; lessons learned from early 2000s applied; quality looks good .
- Ingalls margin/EACs: Neutral EACs driven by people/parts constraints and experience mix; expectation to “turn the corner,” but no timeframe given .
Estimates Context
Q1 2025 vs Wall Street Consensus (S&P Global)
Note: Values retrieved from S&P Global.*
Implications: Strong EPS/EBITDA beats despite revenue softness suggest estimate revisions to margins/EBITDA for FY25/Q2–Q3; unchanged FY25 guide and conservative Q2 margin commentary may temper top-line revisions .
Key Takeaways for Investors
- Execution turning: Q1 margin beat and neutral EACs indicate stabilization; conservative Q2 guide suggests prudence as throughput initiatives ramp .
- Contract structure supports ramp: Cost-type Block V award provides wage and capital incentives to accelerate submarine build rates; supports medium-term upside to shipbuilding growth .
- Mission Technologies delivering: Margin expansion and multiple awards in CEW&S and training underpin FY25 MT targets and diversification beyond shipbuilding .
- Backlog durability: $48B backlog with >$50B targeted awards in 2025–26 positions HII for multi-year growth once post-COVID transitions complete .
- Working capital normalization path: Q1 FCF negative at planned low end; management reiterates FY25 FCF $300–$500M and Q2 FCF $200–$300M as incentives/receipts timing improves .
- Operational catalysts: HD Hyundai MOU, outsourcing ramp, Charleston capacity, and AI/laser/UUV programs are tangible enablers for throughput and margin normalization .
- Risk watch: CVN 80 equipment timing, amphib program performance, and incentive timing remain near-term variables; management tone confident but cautious .
Additional Notes and Cross-References
- Non-GAAP measures referenced (segment operating income/margin, shipbuilding revenue/margin, MT EBITDA/margin, FCF) are defined and reconciled in the 8-K exhibits .
- Q1 achievements include launching DDG 129, christening LPD 30, starting LPD 32 fabrication; Kennedy (CVN 79) 95% compartments turnover; Lionfish UUV deliveries .
- Minimal tariff impact expected due to domestic sourcing and LT agreements .